Pharmacological treatment of left ventricular remodeling: recent trial results

Abstract

Ventricular remodeling, recently characterized as an inhomogeneous entity, has quickly become a therapeutic target. It is assumed that prevention of ventricle remodeling would stop the progression of heart failure. In this review we discuss briefly the issue of ventricular remodeling along with underlying mechanisms leading to cardiac hypertrophy and/or dilatation. Furthermore, we discuss the pharmacologic approaches to prevent left ventricle remodeling, either in animal studies or human trials.